nach oben

Erschienen in:

01.02.2017 | Review Article

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

verfasst von: Jonas Cicenas, Linas Tamosaitis, Kotryna Kvederaviciute, Ricardas Tarvydas, Gintare Staniute, Karthik Kalyan, Edita Meskinyte-Kausiliene, Vaidotas Stankevicius, Mindaugas Valius

Erschienen in: Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Cancers are the group of diseases, which arise because of the uncontrolled behavior of some of the genes in our cells. There are possibilities of gene amplifications, overexpressions, deletions and other anomalies which might lead to the development and spread of cancer. One of the most dangerous ways to the cancers is the mutations of the genes. The mutated genes can start unstoppable proliferation of cells, their uncontrolled motility, protection from apoptosis, the DNA mutation enhancement as well as other anomalies, leading to the cancer. This review focuses on the genes, which are frequently mutated in various cancers and are known to be important in the advance and progression of colorectal cancer and melanoma, namely KRAS, NRAS and BRAF.

Society AAC. American Cancer Society. Cancer Facts & Figures 2016. 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.

Rojas AM, Fuentes G, Rausell A, Valencia A. The Ras protein superfamily: evolutionary tree and role of conserved amino acids. J Cell Biol. 2012;196(2):189–201. doi:10.1083/jcb.201103008.PubMedPubMedCentralCrossRef

Chang EH, Gonda MA, Ellis RW, Scolnick EM, Lowy DR. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci USA. 1982;79(16):4848–52.PubMedPubMedCentralCrossRef

Pai EF, Krengel U, Petsko GA, Goody RS, Kabsch W, Wittinghofer A. Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 a resolution: implications for the mechanism of GTP hydrolysis. EMBO J. 1990;9(8):2351–9.PubMedPubMedCentral

Colicelli J. Human RAS superfamily proteins and related GTPases. Science’s STKE: signal transduction knowledge environment. 2004;2004(250):RE13. doi:10.1126/stke.2502004re13.PubMedPubMedCentral

The NCI’s RAS Initiative. http://www.cancer.gov/research/key-initiatives/ras.

Ras superfamily small G proteins: biology and mechanisms 1: general features, signaling. Wien: Springer; 2014.

Donaldson JG, Honda A. Localization and function of Arf family GTPases. Biochem Soc Trans. 2005;33(Pt 4):639–42. doi:10.1042/BST0330639.PubMedCrossRef

Birsa N, Norkett R, Higgs N, Lopez-Domenech G, Kittler JT. Mitochondrial trafficking in neurons and the role of the Miro family of GTPase proteins. Biochem Soc Trans. 2013;41(6):1525–31. doi:10.1042/BST20130234.PubMedCrossRef

10.

Hanna MGT, Mela I, Wang L, Henderson RM, Chapman ER, Edwardson JM, et al. Sar1 GTPase activity is regulated by membrane curvature. J Biol Chem. 2016;291(3):1014–27. doi:10.1074/jbc.M115.672287.PubMedCrossRef

11.

Mott HR, Owen D. Structures of Ras superfamily effector complexes: what have we learnt in two decades? Crit Rev Biochem Mol Biol. 2015;50(2):85–133. doi:10.3109/10409238.2014.999191.PubMedCrossRef

12.

Vetter IR, Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science. 2001;294(5545):1299–304. doi:10.1126/science.1062023.PubMedCrossRef

13.

Biou V, Cherfils J. Structural principles for the multispecificity of small GTP-binding proteins. Biochemistry. 2004;43(22):6833–40. doi:10.1021/bi049630u.PubMedCrossRef

14.

Olson MF, Marais R. Ras protein signalling. Semin Immunol. 2000;12(1):63–73. doi:10.1006/smim.2000.0208.PubMedCrossRef

15.

Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–51. doi:10.1038/nrd4389.PubMedPubMedCentralCrossRef

16.

Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, et al. The GDI-like solubilizing factor PDE delta sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol. 2011;14(2):148–58. doi:10.1038/ncb2394.PubMedCrossRef

17.

Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2(3):344–58. doi:10.1177/1947601911411084.PubMedPubMedCentralCrossRef

18.

Hanna S, El-Sibai M. Signaling networks of Rho GTPases in cell motility. Cell Signal. 2013;25(10):1955–61. doi:10.1016/j.cellsig.2013.04.009.PubMedCrossRef

19.

Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629–35. doi:10.1038/nature01148.PubMedCrossRef

20.

Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett. 2008;582(14):2093–101. doi:10.1016/j.febslet.2008.04.039.PubMedCrossRef

21.

Tang Y, Olufemi L, Wang MT, Nie D. Role of Rho GTPases in breast cancer. Front Biosci. 2008;13:759–76.PubMedCrossRef

22.

Hutagalung AH, Novick PJ. Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev. 2011;91(1):119–49. doi:10.1152/physrev.00059.2009.PubMedPubMedCentralCrossRef

23.

Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513–25. doi:10.1038/nrm2728.PubMedCrossRef

24.

Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005;118(Pt 5):843–6. doi:10.1242/jcs.01660.PubMedCrossRef

25.

Farnsworth CC, Seabra MC, Ericsson LH, Gelb MH, Glomset JA. Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A. Proc Natl Acad Sci USA. 1994;91(25):11963–7.PubMedPubMedCentralCrossRef

26.

Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta. 2009;1795(2):110–6.PubMed

27.

Rush MG, Drivas G, D’Eustachio P. The small nuclear GTPase Ran: how much does it run? Bioessays. 1996;18(2):103–12. doi:10.1002/bies.950180206.PubMedCrossRef

28.

Li HY, Cao K, Zheng Y. Ran in the spindle checkpoint: a new function for a versatile GTPase. Trends Cell Biol. 2003;13(11):553–7.PubMedCrossRef

29.

Kalab P, Heald R. The RanGTP gradient—a GPS for the mitotic spindle. J Cell Sci. 2008;121(Pt 10):1577–86. doi:10.1242/jcs.005959.PubMedCrossRef

30.

Doherty KJ, McKay C, Chan KK, El-Tanani MK. RAN GTPase as a target for cancer therapy: ran binding proteins. Curr Mol Med. 2011;11(8):686–95.PubMedCrossRef

31.

Pasqualato S, Renault L, Cherfils J. Arf, Arl, Arp and Sar proteins: a family of GTP-binding proteins with a structural device for ‘front-back’ communication. EMBO Rep. 2002;3(11):1035–41. doi:10.1093/embo-reports/kvf221.PubMedPubMedCentralCrossRef

32.

Dong C, Zhang X, Zhou F, Dou H, Duvernay MT, Zhang P, et al. ADP-ribosylation factors modulate the cell surface transport of G protein-coupled receptors. J Pharmacol Exp Ther. 2010;333(1):174–83. doi:10.1124/jpet.109.161489.PubMedPubMedCentralCrossRef

33.

Morgan C, Lewis PD, Hopkins L, Burnell S, Kynaston H, Doak SH. Increased expression of ARF GTPases in prostate cancer tissue. SpringerPlus. 2015;4:342. doi:10.1186/s40064-015-1136-y.PubMedPubMedCentralCrossRef

34.

Donaldson JG. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. J Biol Chem. 2003;278(43):41573–6. doi:10.1074/jbc.R300026200.PubMedCrossRef

35.

Gosal G, Kochut KJ, Kannan N. ProKinO: an ontology for integrative analysis of protein kinases in cancer. PLoS ONE. 2011;6(12):e28782. doi:10.1371/journal.pone.0028782.PubMedPubMedCentralCrossRef

36.

Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14(7):667–78. doi:10.1634/theoncologist.2009-0009.PubMedPubMedCentralCrossRef

37.

Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer. 2006;42(5):636–45. doi:10.1016/j.ejca.2005.11.012.PubMedCrossRef

38.

Cicenas J. The potential role of the EGFR/ERBB2 heterodimer in breast cancer. Expert Opin Ther Pat. 2007;17(6):607–16. doi:10.1517/13543776.17.6.607.CrossRef

39.

Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res. 2005;7(4):R394–401. doi:10.1186/bcr1015.PubMedPubMedCentralCrossRef

40.

Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers. 2008;23(1):1–9.PubMed

41.

Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011;137(10):1409–18. doi:10.1007/s00432-011-1039-4.PubMedCrossRef

42.

Cicenas J, Kalyan K, Sorokinas A, Jatulyte A, Valiunas D, Kaupinis A, et al. Highlights of the latest advances in research on CDK inhibitors. Cancers. 2014;6(4):2224–42. doi:10.3390/cancers6042224.PubMedPubMedCentralCrossRef

43.

Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, et al. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3(10):135. doi:10.3978/j.issn.2305-5839.2015.03.61.PubMedPubMedCentral

44.

Mes-Masson AM, Witte ON. Role of the abl oncogene in chronic myelogenous leukemia. Adv Cancer Res. 1987;49:53–74.PubMedCrossRef

45.

Cicenas J. The Aurora kinase inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2016;142(9):1995–2012. doi:10.1007/s00432-016-2136-1.PubMedCrossRef

46.

Cicenas J, Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol. 2016;33(5):43. doi:10.1007/s12032-016-0758-4.PubMedCrossRef

47.

Roskoski R Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010;399(3):313–7. doi:10.1016/j.bbrc.2010.07.092.PubMedCrossRef

48.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. doi:10.1038/nature00766.PubMedCrossRef

49.

Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14(13):3136–45.PubMedPubMedCentral

50.

Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2011;44(2):133–9. doi:10.1038/ng.1026.PubMedCrossRef

51.

Nicos M, Krawczyk P, Jarosz B, Sawicki M, Michnar M, Trojanowski T, et al. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer. Clin Transl Oncol. 2016;18(10):1039–43. doi:10.1007/s12094-016-1483-3.PubMedPubMedCentralCrossRef

52.

Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370(6490):527–32. doi:10.1038/370527a0.PubMedCrossRef

53.

Eifert C, Wang X, Kokabee L, Kourtidis A, Jain R, Gerdes MJ, et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosomes Cancer. 2013;52(10):961–75. doi:10.1002/gcc.22091.PubMedPubMedCentralCrossRef

54.

Wing MR, Bourdon DM, Harden TK. PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv. 2003;3(5):273–80. doi:10.1124/mi.3.5.273.PubMedCrossRef

55.

Jain K, Basu A. The multifunctional protein kinase C-epsilon in cancer development and progression. Cancers. 2014;6(2):860–78. doi:10.3390/cancers6020860.PubMedPubMedCentralCrossRef

56.

Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem. 2011;11(3):185–99.PubMedCrossRef

57.

Cascone I, Selimoglu R, Ozdemir C, Del Nery E, Yeaman C, White M, et al. Distinct roles of RalA and RalB in the progression of cytokinesis are supported by distinct RalGEFs. EMBO J. 2008;27(18):2375–87. doi:10.1038/emboj.2008.166.PubMedPubMedCentralCrossRef

58.

Guin S, Theodorescu D. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer. Acta Pharmacol Sin. 2015;36(3):291–7. doi:10.1038/aps.2014.129.PubMedPubMedCentralCrossRef

59.

Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45. doi:10.1002/ijc.27711.PubMedCrossRef

60.

Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–808. doi:10.3748/wjg.v20.i22.6786.PubMedPubMedCentralCrossRef

61.

Heinimann K. Toward a molecular classification of colorectal cancer: the role of microsatellite instability status. Front Oncol. 2013;3:272. doi:10.3389/fonc.2013.00272.PubMedPubMedCentralCrossRef

62.

Thiel A, Ristimaki A. Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol. 2013;3:281. doi:10.3389/fonc.2013.00281.PubMedPubMedCentralCrossRef

63.

Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic acids research. 2015;43(Database issue):D805–11. doi:10.1093/nar/gku1075.PubMedCrossRef

64.

Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. doi:10.1038/nature11252.CrossRef

65.

Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277(5324):333–8.PubMedCrossRef

66.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466–74. doi:10.1200/JCO.2009.23.3452.PubMedCrossRef

67.

Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci Rep. 2015;5:8065. doi:10.1038/srep08065.PubMedPubMedCentralCrossRef

68.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53(7):852–64. doi:10.3109/0284186X.2014.895036.PubMedCrossRef

69.

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812–20. doi:10.1001/jama.2010.1535.PubMedCrossRef

70.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855–67.PubMedCrossRef

71.

Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE. 2012;7(10):e47054. doi:10.1371/journal.pone.0047054.PubMedPubMedCentralCrossRef

72.

Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014;120(15):2316–24. doi:10.1002/cncr.28729.PubMedPubMedCentralCrossRef

73.

Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, et al. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010;19(3):157–63. doi:10.1097/PDM.0b013e3181c93fd1.PubMedPubMedCentralCrossRef

74.

Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer. 2015;136(1):83–90. doi:10.1002/ijc.28955.PubMedCrossRef

75.

Janku F, Wheler JJ, Hong DS, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013;8(3):183–8. doi:10.1007/s11523-013-0266-9.PubMedPubMedCentralCrossRef

76.

McCourt C, Dolan O, Gormley G. Malignant melanoma: a pictorial review. Ulster Med J. 2014;83(2):103–10.PubMedPubMedCentral

77.

Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771–6. doi:10.1001/jama.292.22.2771.PubMedCrossRef

78.

Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res. 2010;70(13):5549–57. doi:10.1158/0008-5472.CAN-09-4254.PubMedPubMedCentralCrossRef

79.

Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene. 2007;26(31):4563–70. doi:10.1038/sj.onc.1210239.PubMedCrossRef

80.

Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, et al. Genetic analysis of the ‘uveal melanoma’ C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2015;28(3):357–9. doi:10.1111/pcmr.12345.PubMedCrossRef

81.

Bhatia P, Friedlander P, Zakaria EA, Kandil E. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med. 2015;3(2):24. doi:10.3978/j.issn.2305-5839.2014.12.05.PubMedPubMedCentral

82.

Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012;26(11):1131–55. doi:10.1101/gad.191999.112.PubMedPubMedCentralCrossRef

83.

Cruz F 3rd, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63(18):5761–6.PubMed

84.

Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015;8:157–68. doi:10.2147/OTT.S39096.PubMedPubMedCentralCrossRef

85.

Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol. 2015;72(6):1036–46. doi:10.1016/j.jaad.2015.02.1113.PubMedCrossRef

86.

Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20. doi:10.1038/ng1054.PubMedCrossRef

87.

Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol. 2004;122(2):342–8. doi:10.1046/j.0022-202X.2004.22225.x.PubMedCrossRef

88.

Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873–86. doi:10.1038/nrd3847.PubMedCrossRef

89.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32. doi:10.1016/S1470-2045(14)70012-9.PubMedPubMedCentralCrossRef

90.

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16(13):1389–98. doi:10.1016/S1470-2045(15)00087-X.PubMedCrossRef

91.

Sharma SP. RAS mutations and the development of secondary tumours in patients given BRAF inhibitors. Lancet Oncology. 2011;13:e91.CrossRef

92.

Administration USFaD. Approved drugs. Trametinib and Dabrafenib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htm.

93.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. doi:10.1016/S0140-6736(15)60898-4.PubMedCrossRef

94.

Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51(7):833–40. doi:10.1016/j.ejca.2015.03.004.PubMedCrossRef

95.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65. doi:10.1016/S0140-6736(12)60868-X.PubMedCrossRef

96.

PRNewswire. Binimetinib and encorafenib combination shows promising clinical activity and potential differentiated safety in BRAF-mutant melanoma. http://www.prnewswire.com/news-releases/binimetinib-and-encorafenib-combination-shows-promising-clinical-activity-and-potential-differentiated-safety-in-braf-mutant-melanoma-300091510.html.

97.

Study comparing combination of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in BRAF mutant melanoma (COLUMBUS). NCT01909453. https://clinicaltrials.gov/show/NCT01909453.

98.

Administration USFaD. Approved drugs. Sorafenib (NEXAVAR). http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm376547.htm.

99.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, et al. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2014;74(1):77–84. doi:10.1007/s00280-014-2479-8.PubMedCrossRef

100.

Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer. 2011;105(3):353–9. doi:10.1038/bjc.2011.257.PubMedPubMedCentralCrossRef

101.

Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res. 2009;15(24):7711–8. doi:10.1158/1078-0432.CCR-09-2074.PubMedPubMedCentralCrossRef

102.

Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823–30. doi:10.1200/JCO.2007.15.7636.PubMedCrossRef

103.

Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31(3):373–9. doi:10.1200/JCO.2012.42.1529.PubMedCrossRef

104.

Chin L, Merlino G, DePinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 1998;12(22):3467–81.PubMedCrossRef

105.

Jafari M, Papp T, Kirchner S, Diener U, Henschler D, Burg G, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J Cancer Res Clin Oncol. 1995;121(1):23–30.PubMedCrossRef

106.

Papp T, Pemsel H, Zimmermann R, Bastrop R, Weiss DG, Schiffmann D. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet. 1999;36(8):610–4.PubMedPubMedCentral

107.

Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–9.PubMed

108.

Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24(4):666–72. doi:10.1111/j.1755-148X.2011.00873.x.PubMedCrossRef

109.

Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014–23. doi:10.1002/cncr.26724.PubMedCrossRef

110.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–7. doi:10.1038/nature09626.PubMedPubMedCentralCrossRef

111.

Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012;35(1):66–72. doi:10.1097/CJI.0b013e3182372636.PubMedPubMedCentralCrossRef

112.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015;3(3):288–95. doi:10.1158/2326-6066.CIR-14-0207.PubMedPubMedCentralCrossRef

113.

Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S, et al. KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS ONE. 2014;9(3):e92071. doi:10.1371/journal.pone.0092071.PubMedPubMedCentralCrossRef

114.

Martin V, Zanellato E, Franzetti-Pellanda A, Molinari F, Movilia A, Paganotti A, et al. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. Histol Histopathol. 2014;29(4):513–21. doi:10.14670/HH-29.10.513.PubMed

115.

Lukan N, Strobel P, Willer A, Kripp M, Dinter D, Mai S, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293–9. doi:10.1159/000259615.PubMedCrossRef

Titel: KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
verfasst von: Jonas Cicenas
Linas Tamosaitis
Kotryna Kvederaviciute
Ricardas Tarvydas
Gintare Staniute
Karthik Kalyan
Edita Meskinyte-Kausiliene
Vaidotas Stankevicius
Mindaugas Valius
Publikationsdatum: 01.02.2017
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-016-0879-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Analysis of prognostic value of complete response by PET–CT and further stratification by clinical and biological markers in DLBCL patients

Induction of apoptosis of liver cancer cells by nanosecond pulsed electric fields (nsPEFs)

A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer

A surface tension magnetophoretic device for rare cell isolation and characterization

Extra-pleuric coaxial system for CT-guided percutaneous fine-needle aspiration biopsy (FNAB) of small (≤20 mm) lung nodules: a novel technique using multiplanar reconstruction (MPR) images

Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie